These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma. Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253 [TBL] [Abstract][Full Text] [Related]
9. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Shah MV; Tran ENH; Shah S; Chhetri R; Baranwal A; Ladon D; Shultz C; Al-Kali A; Brown AL; Chen D; Scott HS; Greipp P; Thomas D; Alkhateeb HB; Singhal D; Gangat N; Kumar S; Patnaik MM; Hahn CN; Kok CH; Tefferi A; Hiwase DK Blood Cancer J; 2023 Apr; 13(1):51. PubMed ID: 37041128 [TBL] [Abstract][Full Text] [Related]
10. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102 [TBL] [Abstract][Full Text] [Related]
11. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544 [TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome. Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196 [TBL] [Abstract][Full Text] [Related]
14. Bomben R; Rossi FM; Vit F; Bittolo T; D'Agaro T; Zucchetto A; Tissino E; Pozzo F; Vendramini E; Degan M; Zaina E; Cattarossi I; Varaschin P; Nanni P; Berton M; Braida A; Polesel J; Cohen JA; Santinelli E; Biagi A; Gentile M; Morabito F; Fronza G; Pozzato G; D'Arena G; Olivieri J; Bulian P; Pepper C; Hockaday A; Schuh A; Hillmen P; Rossi D; Chiarenza A; Zaja F; Di Raimondo F; Del Poeta G; Gattei V Clin Cancer Res; 2021 Oct; 27(20):5566-5575. PubMed ID: 34285062 [TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis. Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334 [TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108 [TBL] [Abstract][Full Text] [Related]
17. Low-frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia. Yan B; Chen Q; Xu J; Li W; Xu B; Qiu Y Leukemia; 2020 Jul; 34(7):1816-1827. PubMed ID: 31988438 [TBL] [Abstract][Full Text] [Related]
18. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982 [TBL] [Abstract][Full Text] [Related]
19. Variation characteristics and clinical significance of Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716 [No Abstract] [Full Text] [Related]
20. Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen. Ou J; Xu X; Deng S; Liang H; Cai Z; Li J; Huang Z; Tang B; Wang Z; Zhou Y; Liu X; Liu Q; Zhou H Leuk Lymphoma; 2024 Feb; 65(2):219-227. PubMed ID: 37938093 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]